title: Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.
abstract: Although allogeneic stem cell transplantation is not a standard therapy for multiple myeloma, some patients can benefit from this intense therapy. There are few reports on outcomes after umbilical cord blood transplantation in multiple myeloma, and investigation of this procedure is warranted. We retrospectively analyzed 95 patients, 85 with multiple myeloma and 10 with plasma cell leukemia, receiving single or double umbilical cord blood transplantation from 2001 to 2013. Median follow up was 41 months. The majority of patients received a reduced intensity conditioning. The cumulative incidence of neutrophil engraftment was 97%±3% at 60 days, and that of 100-day acute graft-versus-host disease grade II-IV was 41%±5%. Chronic graft-versus-host disease at two years was 22%±4%. Relapse and non-relapse mortality was 47%±5% and 29%±5% at three years, respectively. Three-year progression-free survival and overall survival were 24%±5% and 40%±5%, respectively. Anti-thymocyte globulin was associated with decreased incidence of acute graft-versus-host disease, higher non-relapse mortality, decreased overall and progression-free survival. Patients with high cytogenetic risk had higher relapse, and worse overall and progression-free survival. In conclusion, umbilical cord blood transplantation is feasible for multiple myeloma patients.
authors.affiliation: Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France Monacord, Centre Scientifique de Monaco, France annalisa.paviglianiti@gmail.com.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Paviglianiti
authors.affiliation: Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France Monacord, Centre Scientifique de Monaco, France.
authors.forename: Erick
authors.initials: E
authors.lastname: Xavier
authors.affiliation: Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France Monacord, Centre Scientifique de Monaco, France Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Ruggeri
authors.affiliation: Département d'Hématologie Clinique, CHU Lapeyronie, Montpellier, France.
authors.forename: Patrice
authors.initials: P
authors.lastname: Ceballos
authors.affiliation: Department Hematology, CHU Besancon, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Deconinck
authors.affiliation: Department of Hematology, Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam, the Netherlands.
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Cornelissen
authors.affiliation: Department Hematology, University Paris IV, Hôpital la Pitié-Salpêtrière, Paris, France.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Nguyen-Quoc
authors.affiliation: Bone Marrow Transplant Unit Clinical Hematology, Hôpital La Miletrie, Poitiers, France.
authors.forename: Natacha
authors.initials: N
authors.lastname: Maillard
authors.affiliation: Servicio de Hematologia, Hospital Universitario y Politecnico La Fe, Valencia, Spain.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Sanz
authors.affiliation: Hematologie Clinique, CHU - Hôpital de l'ARCHET I, Nice, France.
authors.forename: Pierre-Simon
authors.initials: PS
authors.lastname: Rohrlich
authors.affiliation: Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Garderet
authors.affiliation: Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France Monacord, Centre Scientifique de Monaco, France.
authors.forename: Fernanda
authors.initials: F
authors.lastname: Volt
authors.affiliation: Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France Monacord, Centre Scientifique de Monaco, France Department Hematology, Churchill Hospital, Oxford, UK.
authors.forename: Vanderson
authors.initials: V
authors.lastname: Rocha
authors.affiliation: Dept. Stem Cell Transplantation, University Hospital of Hamburg, Germany.
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kroeger
authors.affiliation: Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France Monacord, Centre Scientifique de Monaco, France.
authors.forename: Eliane
authors.initials: E
authors.lastname: Gluckman
authors.affiliation: Département d'Hématologie Clinique, CHU Lapeyronie, Montpellier, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Fegueux
authors.affiliation: Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France INSERM, UMRs 938, Paris, France.
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009026:Mortality; D009101:Multiple Myeloma / Q000175:diagnosis / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D012042:Registries; D012189:Retrospective Studies; D016896:Treatment Outcome; D061349:Unrelated Donors; D055815:Young Adult